Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Nestle pays $2 billion to secure Aimmune's allergy treatment

Stock MarketsAug 31, 2020 07:05AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Logo is pictured on the Nestle research center in Lausanne 2/2

By Silke Koltrowitz

ZURICH (Reuters) - Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics (NASDAQ:AIMT), as the Swiss company expands its fast-growing health science business.

Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to open up a new area of business between food and pharma.

Nestle said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around 25.6%, at $2.6 billion.

"Aimmune has $261 million in cash and $134 million in debt. With our prior investment of $473 million in Aimmune, we'll be making a cash payment of just under $2 billion," NHS head Greg Behar told Reuters in an interview.

Nestle estimates that up to 240 million people worldwide suffer from food allergies, with peanut allergy being the most common, and with Aimmune, NHS will have prevention, diagnostic and medical treatment options available, Behar said.

Aimmune's Palforzia peanut allergy treatment, which recently gained U.S. approval for children, has sales potential of $1 billion, Behar said. The deal is expected to add to organic growth in 2021 and to cash earnings by 2022/23.

The NHS business was on track to more than double sales by 2022, from 2 billion Swiss francs ($2.21 billion) in 2014, and was expected to close 2020 at 3.3 billion francs, he added.

"(Palforzia) has 12 years of exclusivity, global rollout will follow and they have the technology platform for other food allergies in development," Behar said.

Nestle, whose shares were up 0.6% at 0739 GMT, is offering a 174% premium to Aimmune's closing share price of $12.60 on Aug. 28. Aimmune shares hit a record high in January when Palforzia was approved, then dropped during the coronavirus crisis.

Vontobel analyst Jean-Philippe Bertschy said the deal was "another milestone" for NHS after it bought Atrium in 2017.

Nestle has a market capitalisation of just under 317 billion Swiss francs ($350 billion), Refinitiv data showed.

Nestle pays $2 billion to secure Aimmune's allergy treatment
 

Related Articles

Yields slip, stocks struggle as economic fears grow
Yields slip, stocks struggle as economic fears grow By Reuters - May 16, 2022 40

By Herbert Lash NEW YORK (Reuters) - U.S. stocks closed mixed on Monday as downbeat Chinese and New York state data kindled recession fears, but the 10-year Treasury note's yield...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Jurgen Daub
Jurgen Daub Aug 31, 2020 10:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
makes sense and closes the circle. first you sell processed food to make people sick. then you develop and sell the remedies for the initial illness, then you get the side effects, then you develop and semm the medication to treat the sideffects and so on and on, greatest business to melk the cow
Evan cole
Evan cole Aug 31, 2020 2:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
mergers and acquisitions to they over leverage and fail, then get bailed out by the taxpayer
Zach Lohman
Zach Lohman Aug 31, 2020 2:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not this one. Nestle’s got plenty of money and the transaction’s tiny for it.
Plopseven Schwartz
Plopseven Schwartz Aug 31, 2020 1:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Can’t wait for them to poison baby formulua again. I wouldn’t trust Nestle with anything.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email